MEDIXALL GROUP, INC. (OTCMKTS:MDXL) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
On June 24, 2020, MediXall Group, Inc. (the “Company”) filed with the Secretary of State of the State of Nevada (the “Secretary of State”) a certificate of designation (the “Certificate of Designation”) of Series B Convertible Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”). The Certificate of Designation was effective upon filing with the Secretary of State and designated a new series of preferred stock of the Company as Series B Convertible Preferred Stock with 4,000,000 shares authorized for issuance. The Series B Preferred Stock has a stated value of $1.00 per share (the “Stated Value”).
Upon the occurrence of the events as set forth in paragraph (a) or (b) below, each share of Series B Preferred Stock shall be converted into four (the “Conversion Ratio”) fully paid and non-assessable shares of common stock or any shares of capital stock or other securities of the Company into which such common stock shall hereafter be changed or reclassified (the “Conversion Shares”) as set forth in the Certificate of Designation.
(a) Automatic Conversion
Immediately upon the listing of the common stock for trading on the New York Stock Exchange or the Nasdaq Stock Market, all of the issued and outstanding shares of Series B Preferred Stock shall automatically be converted into Conversion Shares without any further action of any holder of Series B Preferred Stock (each, a “Series B Holder” and collectively, “Series B Holders”).
(b) Optional Conversion
A Series B Holder shall have the right from time to time, and at any time during the period beginning on the date which is six months following the date that the Series B Preferred Stock is initially issued (the “Issuance Date”) and prior to any automatic conversion as provided in the Certificate of Designation, to convert all or any part of the outstanding Series B Preferred Stock held by such Series B Holder into Conversion Shares at the Conversion Ratio as determined as provided in the Certificate of Designation, subject to limitations set forth in the Certificate of Designation.
Series B Holders will be entitled to receive a quarterly dividend commencing on the Issuance Date, until the conversion of the Series B Preferred Stock, at the rate of 8% per annum of the Stated Value (the “Series B Dividend”). The Series B Dividend will be cumulative, shall accrue quarterly from the Issuance Date, and be paid via the issuance of a number of shares of common stock of the Company equal to (1) the dollar amount of the Series B Dividend being paid, divided by (2) $0.25 (the “Stock Dividend”). The Stock Dividend shall be paid via the issuance to the applicable Series B Holder of the applicable shares of common stock via book entry in the books and records of the Company.
Each share of Series B Preferred Stock shall have a number of votes on any matter submitted to the holders of the Company’s common stock, or any class thereof, for a vote, equal to the number of Conversion Shares into which the Series B Preferred Stock is then convertible, and shall vote together with the common stock, or any class thereof, as applicable, as one class on such matter for as long as the share of Series B Preferred Stock is issued and outstanding.
The Series B Preferred Stock is not redeemable at the election of the Company but may be redeemed upon the agreement of the Company and the applicable Series B Holder.
The foregoing description of the Certificate of Designation does not purport to be complete and is qualified in its entirety by reference to the Certificate of Designation, a copy of which is filed as Exhibit 3.1 to this Current Report and is incorporated herein by reference.